NCT03526822 |
|
Prospective Cohort of Patients With Newly Diagnosed Glioblastoma Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features
|
View
|
NCT03631836 |
|
Phase I Study of Monoclonal Antibondy GS 5745 an Matix Metalloproteinase 9 MMP9 Mab Inhibitor in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
|
View
|
NCT02823925 |
|
Bisphosphonate Therapy in MONA Spectrum Disorder
|
View
|
NCT00935051 |
|
Matrix Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-1 MMP-1TIMP-1 Ratio and Diabetic Foot Ulcers
|
View
|
NCT05627323 |
|
CAR T Cells in Patients With MMP2 Recurrent or Progressive Glioblastoma
|
View
|
NCT04214392 |
|
Chimeric Antigen Receptor CAR T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2 Recurrent or Progressive Glioblastoma
|
View
|
NCT03185039 |
|
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
|
View
|
NCT04335526 |
|
A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles
|
View
|
NCT06584409 |
|
Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP
|
View
|